11 documents found, page 1 of 2

Asdas responses in patients with axial spondyloarthritis starting bdmards: resu...

ASAS and EULAR recommend the use of an improvement ≥1.1 in ASDAS at 12 weeks to determine the continuation of a bDMARD. However, it is debated whether improvements can occur and whether patients’ characteristics influence (time to) response.

Neutrophile to lymphocyte and platelet to lymphocyte ratios predict clinical re...

Objective: We aim to study association between neutrophile to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios and disease activity, and their value to predict bDMARD response. Methods: A set of spondylarthritis (SpA) patients under bDMARD registered in the Reuma.pt registry was studied. Sociodemographic, clinical and laboratorial variables were assessed on bDMARD initiation, 6, 12, 18 and 24 months (M)...

Prevalence and clinical characteristics of late Onset Axial Spondyloarthritis: ...

Axial spondyloarthritis (axSpA) typically starts before the fourth decade oflife. Consistent with that, the Assessment of SpondyloArthritis international Society (ASAS)classification criteria for axSpA should be applied only in patients with chronic back pain startingbefore 45 years of age. It has, however, been suggested that axSpA can sometimes start later in lifewith a distinctive phenotype, the so-called ‘l...

Immune-mediated skin lesions related to biological disease-modifying antirheuma...

Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the treatment of chronic inflammatory rheumatic diseases. However, the physician and the patient should be aware of possible adverse reactions. Skin is one of the most frequent organs involved in bDMARD adverse reactions and immune-mediated skin lesions (IMSL) have rarely been described before in cohort studies and their incidence is...

Adalimumab and number of previous biological disease-modifying antirheumatic dr...

Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic p...

Portuguese Recommendations for the use of biological therapies in patients with...

Portuguese recommendations for the use of biological therapies in patients with...

Portuguese recommendations for the use of methotrexate in rheumatic diseases – ...

Caracterização do efetivo caprino da raça Boer em Portugal

A raça caprina Boer, originária da Africa do Sul, é considerada uma das raças mais importantes para a produção de carne, apresentando uma excelente capacidade de adaptação, sendo por isso explorada, com sucesso, em várias zonas do globo, com condições meteorológicas muito variadas. Atualmente, a exploração de caprinos desta raça em Portugal ainda tem uma expressão bastante diminuta, tendo sido concluída a criaç...

Caraterização das explorações de caprinos da raça serrana, ecótipo ribatejano, ...

O trabalho carateriza o efetivo e as condições de exploração da raça caprina Serrana, ecótipo Ribatejano, na região do Ribatejo. Baseia-se em registos disponibilizados pela ACORO - Associação de Criadores de Caprinos, Ovinos e Bovinos do Ribatejo e Oeste e inquéritos realizados junto dos caprinicultores, com efetivos inscritos no Livro Genealógico, pertencentes à sua área de influência. Obtiveram-se, ainda, dad...